ERBB2 and neoplasm: Trastuzumab alone did not reduce primary tumor size but significantly reduced brain GFP signal by 17% ± 8% and 26% ± 7% in the 4T1-HER2<sup>WT</sup> and 4T1-HER2<sup>YVMA</sup> models, respectively.